Study of IMC-P115C in Advanced PRAME-Positive Cancers
Launched by IMMUNOCORE LTD ·
Trial Information
Current as of September 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medicine called IMC-P115C to see if it is safe and helpful for people with advanced cancers that have a specific marker called PRAME. This medicine is designed to target cancer cells with PRAME and may be used alone or together with other standard cancer treatments. The study is in an early phase, which means it is the first time this medicine is being tested in people.
People who might be able to join this study are adults aged 65 to 74 who have advanced cancers that test positive for PRAME and also have a specific genetic type called HLA-A*02:01. Both men and women can participate. If you join, you will receive the new medicine and be closely monitored by the medical team to check for safety and to see if the treatment is working. The study is currently looking for participants, so if you or a family member meet these criteria, you may want to talk to your doctor about this opportunity.
Gender
ALL
Eligibility criteria
About Immunocore Ltd
Immunocore Ltd. is a pioneering biotechnology company focused on transforming the treatment landscape for cancer and other serious diseases through its innovative T-cell receptor (TCR) technology. By harnessing the unique capabilities of T-cells to recognize and target disease-associated antigens, Immunocore is dedicated to developing novel immunotherapies that aim to enhance patient outcomes. The company’s robust pipeline includes advanced clinical trials designed to evaluate the safety and efficacy of its proprietary TCR-based therapies, underscoring its commitment to precision medicine and the advancement of next-generation immuno-oncology solutions. With a strong emphasis on scientific excellence and collaboration, Immunocore is positioned at the forefront of therapeutic innovation in the biopharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported